Cash and Short Term Investments (Quarterly) Chart

View Cash and Short Term Investments (Quarterly) for AMRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash and Short Term Investments (Quarterly) Chart
Start Trial

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 136.28M
March 31, 2026 201.83M
December 31, 2025 310.87M
September 30, 2025 235.98M
June 30, 2025 81.19M
March 31, 2025 65.77M
December 31, 2024 118.42M
September 30, 2024 78.34M
June 30, 2024 49.62M
March 31, 2024 51.62M
December 31, 2023 99.11M
September 30, 2023 95.61M
June 30, 2023 114.58M
March 31, 2023 151.07M
December 31, 2022 35.23M
September 30, 2022 95.89M
June 30, 2022 98.18M
March 31, 2022 216.54M
December 31, 2021 256.74M
September 30, 2021 310.62M
June 30, 2021 283.15M
March 31, 2021 455.81M
December 31, 2020 347.12M
September 30, 2020 283.65M
June 30, 2020 268.27M
Date Value
March 31, 2020 406.92M
December 31, 2019 152.82M
September 30, 2019 217.06M
June 30, 2019 57.02M
March 31, 2019 66.74M
December 31, 2018 218.78M
September 30, 2018 172.19M
June 30, 2018 68.59M
March 31, 2018 0.00
December 31, 2017 77.92M
September 30, 2017
June 30, 2017
March 31, 2017 157.25M
December 31, 2016 180.13M
September 30, 2016 232.12M
June 30, 2016 366.85M
March 31, 2016 412.18M
December 31, 2015 340.35M
September 30, 2015 318.40M
June 30, 2015 190.29M
March 31, 2015 163.09M
December 31, 2014 414.86M
September 30, 2014 442.52M
June 30, 2014 413.03M
March 31, 2014 390.43M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Liquidia Corp. 284.18M
Eli Lilly & Co. 8.95B
Viatris, Inc. 1.410B
Pfizer Inc. 11.70B
Indivior Pharmaceuticals, Inc. 222.00M